Literature DB >> 22484631

Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities.

I A Voutsadakis1.   

Abstract

Malignant mixed Müllerian tumours (malignant mixed mesodermal tumours, MMMT) of the uterus are metaplastic carcinomas with a sarcomatous component and thus they are also called carcinosarcomas. It has now been accepted that the sarcomatous component is derived from epithelial elements that have undergone metaplasia. The process that produces this metaplasia is epithelial to mesenchymal transition (EMT), which has recently been described as a neoplasia-associated programme shared with embryonic development and enabling neoplastic cells to move and metastasise. The ubiquitin proteasome system (UPS) regulates the turnover and functions of hundreds of cellular proteins. It plays important roles in EMT by being involved in the regulation of several pathways participating in the execution of this metastasis-associated programme. In this review the specifi c role of UPS in EMT of MMMT is discussed and therapeutic opportunities from UPS manipulations are proposed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22484631     DOI: 10.1007/s12094-012-0792-4

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  127 in total

1.  Smad4 protein stability is regulated by ubiquitin ligase SCF beta-TrCP1.

Authors:  Mei Wan; Yi Tang; Ewan M Tytler; Chongyuan Lu; Bingwen Jin; Selwyn M Vickers; Lei Yang; Xingming Shi; Xu Cao
Journal:  J Biol Chem       Date:  2004-02-26       Impact factor: 5.157

2.  The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation.

Authors:  Claudia Esser; Martin Scheffner; Jörg Höhfeld
Journal:  J Biol Chem       Date:  2005-05-23       Impact factor: 5.157

3.  Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma.

Authors:  Izumi Nishimura; Yoshihiro Ohishi; Yoshinao Oda; Junji Kishimoto; Masafumi Yasunaga; Emi Okuma; Hiroaki Kobayashi; Norio Wake; Masazumi Tsuneyoshi
Journal:  Virchows Arch       Date:  2010-11-03       Impact factor: 4.064

4.  Oestrogen-induced epithelial-mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis.

Authors:  Yi-Jen Chen; Hsin-Yang Li; Chi-Hung Huang; Nae-Fang Twu; Ming-Shyen Yen; Peng-Hui Wang; Teh-Ying Chou; Yen-Ni Liu; Kuan-Chong Chao; Muh-Hwa Yang
Journal:  J Pathol       Date:  2010-11       Impact factor: 7.996

Review 5.  Uterine carcinosarcoma.

Authors:  Sherif A El-Nashar; Andrea Mariani
Journal:  Clin Obstet Gynecol       Date:  2011-06       Impact factor: 2.190

Review 6.  Proteasome inhibitor, bortezomib, for myeloma and lymphoma.

Authors:  Kensei Tobinai
Journal:  Int J Clin Oncol       Date:  2007-10-22       Impact factor: 3.402

7.  Autocrine motility factor stimulates the invasiveness of malignant cells as well as up-regulation of matrix metalloproteinase-3 expression via a MAPK pathway.

Authors:  Arayo Haga; Tatsuyoshi Funasaka; Yoshihiro Deyashiki; Avraham Raz
Journal:  FEBS Lett       Date:  2008-05-15       Impact factor: 4.124

8.  p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo.

Authors:  Manran Liu; Mathew C Casimiro; Chenguang Wang; L Andrew Shirley; Xuanmao Jiao; Sanjay Katiyar; Xiaoming Ju; Zhiping Li; Zuoren Yu; Jie Zhou; Michael Johnson; Paolo Fortina; Terry Hyslop; Jolene J Windle; Richard G Pestell
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-26       Impact factor: 11.205

9.  Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF.

Authors:  Deo Prakash Pandey; Rosamaria Lappano; Lidia Albanito; Antonio Madeo; Marcello Maggiolini; Didier Picard
Journal:  EMBO J       Date:  2009-01-15       Impact factor: 11.598

10.  Systematic in vivo RNAi analysis identifies IAPs as NEDD8-E3 ligases.

Authors:  Meike Broemer; Tencho Tenev; Kristoffer T G Rigbolt; Sophie Hempel; Blagoy Blagoev; John Silke; Mark Ditzel; Pascal Meier
Journal:  Mol Cell       Date:  2010-12-10       Impact factor: 17.970

View more
  6 in total

1.  Degradation of the transcription factor Twist, an oncoprotein that promotes cancer metastasis.

Authors:  Jiateng Zhong; Kohei Ogura; Zhiwei Wang; Hiroyuki Inuzuka
Journal:  Discov Med       Date:  2013-01       Impact factor: 2.970

2.  Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

Authors:  Carlton L Schwab; Diana P English; Jonathan Black; Stefania Bellone; Salvatore Lopez; Emiliano Cocco; Elena Bonazzoli; Beatrice Bussi; Federica Predolini; Francesca Ferrari; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2015-08-08       Impact factor: 5.482

3.  Large cell neuroendocrine carcinoma of the ovary: A pathologic entity in search of clinical identity.

Authors:  Ioannis A Voutsadakis
Journal:  World J Clin Oncol       Date:  2014-05-10

4.  SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.

Authors:  Gulden Menderes; Elena Bonazzoli; Stefania Bellone; Jonathan Black; Federica Predolini; Francesca Pettinella; Alice Masserdotti; Luca Zammataro; Gary Altwerger; Natalia Buza; Pei Hui; Serena Wong; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Clin Cancer Res       Date:  2017-07-05       Impact factor: 12.531

5.  A rare presentation of carcinosarcoma of the bone in a young female; response with gemcitabine and docetaxel.

Authors:  Nicholas King; Keshav Kukreja; Albina Murzabdillaeva; Yasir Ali; Jason Willis; Abhishek Maiti; Hilary Ma; Joan Bull
Journal:  Clin Sarcoma Res       Date:  2019-07-02

6.  Apelin inhibited epithelial-mesenchymal transition of podocytes in diabetic mice through downregulating immunoproteasome subunits β5i.

Authors:  Jiming Yin; Yangjia Wang; Jing Chang; Bin Li; Jia Zhang; Yu Liu; Song Lai; Ying Jiang; Huihua Li; Xiangjun Zeng
Journal:  Cell Death Dis       Date:  2018-10-09       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.